AbstractBackground and objective Serum creatinine (Scr)-based equations, particularly the Schwartz equation, are widely used to estimate glomerular filtration rate (eGFR) and guide drug dosing in pediatric intensive care unit (PICU) patients. However, Scr may be influenced by non-renal factors, potentially...

Abstract Background/objectives KRAS-mutant lung adenocarcinoma remains without effective targeted therapies for most patients, particularly those with non-G12C alleles or resistance to KRASG12C inhibitors. RAF1 is essential for KRAS-driven tumor maintenance through kinase-independent survival functions, making it an attractive candidate for...

ARTS Trial: Adjuvant Aumolertinib in Resected EGFR-Mutated NSCLC ARTS trial evaluated aumolertinib as adjuvant therapy in patients with completely resected stage II–IIIB EGFR-mutated non-small-cell lung cancer, a population that remains at high risk of recurrence despite surgery and standard postoperative...

The overexpression of epidermal growth factor receptor (EGFR) in various cancer types makes it an attractive target for therapeutic intervention. In this study, we designed a novel peptibody, FcIgG-GE11-Melittin, by fusing Melittin, a cytotoxic peptide from bee venom, to an...

AbstractPurpose Differentiated thyroid cancer (DTC) typically has a favourable prognosis, while advanced forms of these tumours exhibit aggressive behaviour, leading to decreased survival. Lenvatinib has demonstrated effectiveness in managing advanced DTC. However, its long-term efficacy is compromised by resistance mechanisms,...

Abstract Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality worldwide, emphasizing the need for novel therapeutic strategies. In this study, we demonstrate that homoyessotoxin (hYTXs), a marine-derived natural compound, exerts potent anti-NSCLC progression. Network pharmacology, molecular...